相关实验视频

Updated: May 6, 2026

High-frequency High-resolution Echocardiography: First Evidence on Non-invasive Repeated Measure of Myocardial Strain, Contractility, and Mitral Regurgitation in the Ischemia-reperfused Murine Heart

High-frequency High-resolution Echocardiography: First Evidence on Non-invasive Repeated Measure of Myocardial Strain, Contractility, and Mitral Regurgitation in the Ischemia-reperfused Murine Heart

Published on: July 9, 2010

左心室应变的区分能力在轻微减少的喷射断裂心力衰竭中

Fa-Po Chung^1,2, Tze-Fan Chao^1,2, An-Sheng Lee^3,4

¹Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

|June 28, 2024

概括

左心室 (LV) 菌株在心力衰竭中提供比左心室喷射分数 (LVEF) 更好的预后洞察力,轻微减少喷射分数 (HFmrEF). 此外,LV菌株还有助于识别受益于血管新生素受体-尼普利辛抑制剂 (ARNi) 治疗的患者.

科学领域:

心脏病学心脏病学
心脏衰竭研究研究
心肌机械学心肌机械学

背景情况:

左心室 (LV) 缩应变是潜在的比LV射出率 (LVEF) 更敏感的心肌指标.
有限的数据存在于LV菌株在风险分层中的作用和识别对轻微减少喷射分数 (HFmrEF) 的心力衰竭中血管激素受体-尼普利辛抑制剂 (ARNi) 治疗的响应者.

研究的目的:

评估LV菌株是否在HFmrEF患者中提供超出LVEF的预后信息.
要确定LV菌株是否可以在HFmrEF中区分ARNi的治疗疗效.

主要方法:

在1,075名HFmrEF患者中量化了LVEF和LV菌株.
计算了MAGGIC风险评分,并执行了Cox比例危险建模以进行时间到事件分析.
使用限制性立方脊柱曲线来建模ARNi效应与基于LVEF或LV菌株的宁-血管素系统抑制剂.

主要成果:

LV菌株与MAGGIC心脏风险相反相关 (系数: -0.14,P < 0.001).
LV菌株独立预测临床结果,在总生存预测方面表现优于LVEF (哈雷尔C指数:0.71与0.56).
下方LV菌株,而不是LVEF,始终表明有有益的ARNi效应.

结论:

在HFmrEF中,LV菌株是一个有价值的缩标志物.
与LVEF相比,LV菌株在ARNi治疗方面提供了更好的预后和治疗歧视.

关键词:

LV喷射分数的LV喷射分数这是一种LV菌株.马吉克 (Maggic) 的得分血管激素受体 neprilysin 抑制剂 (ARNi) 的使用.心力衰竭与轻微减少的射出分数.氨酸- ангиотензин系统抑制剂 (RASi)

更多相关视频

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

相关概念视频

Mitral Stenosis I: Introduction

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...